Susvimo Implant for Wet Macular Degeneration in Sarasota, FL
A long-acting treatment that can reduce how often you need eye injections.
Susvimo is an FDA-approved implant designed to deliver continuous medication for wet macular degeneration, helping maintain vision with far fewer in-office injections. Our retina specialists evaluate whether Susvimo is a good option for your treatment plan and guide you through the process from consultation to follow-up care.
Patients grow tired of the multiple eye injections required to treat wet macular degeneration. These injections can be anxiety-provoking, uncomfortable, and as frequent as every month. Fortunately, help is on the way. A new FDA-approved treatment, Susvimo, has arrived that is indicated for twice-per-year dosing. In addition to this innovative product, a new injectable medication, Vabysmo, has gained FDA approval for dosing up to 16 weeks. Lastly, there are other medications being assessed in clinical trials that may soon provide longer-lasting dosing than what is currently available.
It Is Worth Saying, Eye Injections Are a Miracle
Eye injections for age related macular degeneration have been around since the early 2000’s. Originally, anti-vascular endothelial growth factor (anti-VEGF) medication was designed to inhibit the growth of cancer, but it was quickly proven to stop and reverse vision loss from wet macular degeneration. These miracle drugs have provided the greatest prevention of blindness since the advent of cataract surgery. Patients who would have been blind twenty years ago have maintained reading and driving vision thanks to these wonderful medications.
The Problem of Frequent Eye Injections
Many patients with wet macular degeneration are required to get injections of medication into their eye every 4-6 weeks. These frequent visits can be stressful on the schedule and the psyche of macular degeneration patients. A typical injection visit lasts 45-minutes to an hour and sometimes involves dilation, retinal imaging, and multiple-drop preparation in advance of the eye injection. The injection itself can sometimes be uncomfortable or cause bleeding on the surface of the eye. Afterwards, some patients feel scratchy or irritated for the rest of the day. The process gets repeated every visit indefinitely, with some patients receiving greater than fifty injections in their lifetime. Oftentimes, life events prevent patients from coming to their appointments on schedule, which results in loss of vision over time.
Injection Frequency Has Been Extending
Ever since Lucentis was approved for monthly dosing in 2006, physicians have been looking for ways to perform injections less-frequently while maintaining visual acuity gains. Initially, an as-needed dosing regimen was attempted, where patients only received medication for recurrences of macular leakage.
Unfortunately, this approach was found to cause loss of vision over time compared to monthly dosing. A more conservative paradigm was developed for decreasing injection frequency, called ‘Treat and Extend.’ In this method, injection visits are slowly spread out until leakage occurs, at which point the injection interval is maintained at the maximum-extended interval. This has been shown to achieve similar vision gains to monthly treatments, but with fewer injections.
Another way that injection frequency has been extended is by the development of more powerful anti-VEGF medication. Eylea was approved for 8-week dosing in 2011, and then for 12-week dosing in 2018. Another medication, Bevou, was approved for 12-week dosing in 2019, but fell out of favor due to a higher rate of ocular inflammation.
A new injectable medication, Vabysmo, has recently gained FDA approval for up to 16-week dosing. This novel treatment blocks VEGF as well as a second chemical signal for new blood vessel growth called ANG-2. Vabysmo will be available this year to patients with both wet macular degeneration and diabetic retinopathy.
Other attempts at extending injection intervals have been unsuccessful, include retinal laser, focal radiation, eye drops, and oral medication.
Susvimo: FDA Approved Eye Injections that last up to 6 months
Doctors and scientists have been searching for additional ways to extend eye injection intervals. One method that just received FDA-clearance is Susvimo, which is dosed with an injection in the clinic every 6 months. Susvimo is an intraocular implant that is placed within the eye through an incision and covered with the thin membrane on the surface of the eye called the conjunctiva. It is pre-loaded with medication and delivers a steady-state of drug for at least 6 months, with less than 2% of patients requiring another injection prior to that time. At the end of 6 months, the implant is refilled with an injection in the clinic.
The main risk of Susvimo is post-operative infection, which occurred in 2% of patients during the clinical trial. Infection in the eye is a serious threat to vision, and careful coverage of the implant with the conjunctiva is necessary to reduce the risk of this complication.
Who is Susvimo for?
The best candidates for Susvimo implantation are those who are currently receiving eye injections every 4-6 weeks. The risk/benefit profile of this procedure favors those with better vision in their non-operative eye. Patients who only get injections in one eye are also favored given that they will only need one implant procedure to see the benefits of less-frequent eye injection appointments. Those who have difficulty making frequent appointments due to their schedule, disability, or lack of transportation are obvious winners with Susvimo.
Susvimo FAQs
What is Susvimo?
Susvimo is an FDA-approved, long-acting implant used to treat wet macular degeneration. It continuously delivers anti-VEGF medication inside the eye and reduces how often patients need traditional eye injections.
Unlike standard injections that are given every four to eight weeks, Susvimo is surgically implanted once and then refilled in the office approximately every six months.
The implant provides a steady, controlled release of medication to maintain vision while reducing the burden of frequent injection visits.
How does the Susvimo implant work?
Susvimo is a small, refillable implant that is surgically placed in the wall of the eye to deliver continuous anti-VEGF medication for wet macular degeneration. Instead of receiving frequent injections, the implant slowly releases medication at a steady rate over several months.
The medication inside the implant is ranibizumab, an anti-VEGF drug that blocks abnormal blood vessel growth and leakage under the retina. By maintaining consistent levels of medication inside the eye, Susvimo helps control macular swelling without the ups and downs that can occur between monthly injections.
Approximately every six months, the implant is refilled in the office through a specialized needle system. The refill procedure does not require repeat surgery.
This continuous delivery system allows many patients to maintain stable vision while reducing the number of treatment visits.
How often does Susvimo need to be refilled?
Susvimo is typically refilled every six months. After the implant is surgically placed, it continuously releases medication inside the eye. At approximately six-month intervals, your retina specialist performs an in-office refill procedure to replenish the medication reservoir.
The refill is not another surgery. It is performed in the office using a specialized needle system designed specifically for the implant.
Clinical studies showed that most patients maintained stable vision with refills every 24 weeks. Your retina specialist will monitor your retina closely to ensure the medication is controlling leakage before and after each refill visit.
Who is a good candidate for Susvimo?
Susvimo is best suited for patients with wet macular degeneration who require frequent anti-VEGF injections to keep their disease under control.
Ideal candidates typically:
- Have demonstrated a good response to traditional anti-VEGF injections
- Require frequent injections to maintain stable vision
- Are seeking to reduce the burden of frequent office visits
- Have stable anatomy in the eye without active infection or severe inflammation
Patients who receive injections in only one eye are often strong candidates, since the implant can reduce treatment frequency on that side. Susvimo may also be especially helpful for individuals who have difficulty attending frequent appointments due to transportation, travel, or scheduling limitations.
Because implantation requires a surgical procedure, overall eye health and individual risk factors are carefully evaluated. A retina specialist determines candidacy after a detailed examination and discussion of risks and benefits.
Is the Susvimo implant surgery painful?
Susvimo implantation is performed under local anesthesia and is generally not painful. The eye is completely numbed before the procedure, and patients may also receive mild sedation to remain comfortable.
During the surgery, you may feel pressure or awareness of movement, but sharp pain is uncommon. The procedure is performed in a controlled surgical setting and typically takes less than an hour.
After surgery, it is normal to experience some irritation, redness, or mild discomfort for several days. Prescription eye drops are used to reduce inflammation and prevent infection while the eye heals.
Your retina specialist will provide detailed post-operative instructions and closely monitor healing to ensure a safe recovery.
What are the risks of the Susvimo implant?
Susvimo implantation carries higher risk than a standard in-office injection because it involves a surgical procedure. While many patients do well, it is important to understand the potential complications.
The most serious risk is infection inside the eye, called endophthalmitis. In early clinical trials, infection occurred in approximately 2 percent of patients. Because the implant remains in the eye long-term, careful surgical technique and follow-up are critical to reduce this risk.
Other potential risks include:
- Inflammation inside the eye
- Conjunctival erosion or breakdown over the implant
- Bleeding
- Retinal detachment
- Temporary increase in eye pressure
These risks are uncommon but can be vision-threatening if not treated promptly.
Your retina specialist will carefully evaluate whether the benefit of reducing frequent injections outweighs the surgical risk based on your individual eye health and treatment history.
How does Susvimo compare to regular eye injections?
Susvimo and regular anti-VEGF injections both treat wet macular degeneration by delivering medication that blocks abnormal blood vessel growth and leakage under the retina. The difference lies in how the medication is delivered and how often treatment is required.
Traditional eye injections are given directly into the eye every four to eight weeks, depending on disease activity. This approach is highly effective but requires frequent office visits.
Susvimo, on the other hand, is a surgically implanted reservoir that continuously releases medication over several months. Instead of monthly injections, the implant is typically refilled every six months.
The benefit of Susvimo is reduced treatment burden and fewer injection visits. However, it requires a surgical procedure and carries a higher upfront risk compared to standard injections.
Both approaches are effective. The choice depends on how well your eye responds to injections, how frequently treatment is needed, and whether reducing visit frequency outweighs the surgical risks in your specific case.
How do I get Susvimo treatment in Sarasota?
The first step in receiving Susvimo treatment is scheduling a consultation with a retina specialist who offers the implant procedure. During your visit, your doctor will perform a comprehensive dilated exam and retinal imaging to determine whether you are a good candidate.
Susvimo is typically recommended for patients with wet macular degeneration who are already responding well to anti-VEGF injections but require frequent treatments to maintain stable vision.
If you are a candidate, the procedure will be scheduled at a surgical facility. After implantation, your retina specialist will monitor healing and schedule refill visits approximately every six months.
At Shane Retina, Susvimo evaluations and implant procedures are offered at our Sarasota and Venice locations. Our team guides patients through candidacy assessment, surgical planning, post-operative care, and long-term refill management to ensure safe and effective treatment.
Where to Get Susvimo Implant Treatment for Wet Macular Degeneration in Sarasota and Venice
You can receive Susvimo implant evaluation and treatment for wet macular degeneration at our Shane Retina locations throughout Sarasota and Venice, Florida. Our retina specialists assess candidacy for Susvimo and provide long-acting treatment options designed to reduce injection frequency while maintaining stable vision.
Sarasota - University Parkway Office
Located just west of I-75 on University Parkway in University Health Park.
Our University Parkway location serves patients from Sarasota, Lakewood Ranch, Bradenton, and surrounding areas of Manatee County. This office provides evaluation and ongoing management for wet macular degeneration, including Susvimo implant placement and refill visits for patients seeking fewer eye injections over time.
Sarasota - South Tamiami Trail Office
Located on South Tamiami Trail just south of Bee Ridge Road.
Our South Tamiami Trail location serves patients throughout Sarasota, Siesta Key, and nearby Sarasota County communities. Patients at this office receive personalized treatment planning for wet macular degeneration, including assessment for Susvimo implantation and coordinated follow-up care after placement.
Venice Retina Office
Located in central Venice near Venetia Bay Boulevard.
Patients in Venice, North Port, Englewood, and surrounding areas of southern Sarasota County can receive Susvimo implant evaluation and long-term treatment for wet macular degeneration at this location. Our team provides ongoing care focused on reducing treatment burden while preserving central vision.
Other Opportunities to Extend Eye Injection Intervals
Susvimo is not the last innovation that will allow retina specialists to extend eye injection intervals. Several drugs are in clinical trials that are more potent VEGF inhibitors than the current FDA-approved medications. Other investigational drugs target molecules along the wet macular degeneration pathway other than VEGF.
Most exciting in the research of wet macular degeneration treatment is gene therapy. While gene therapy trials are in their preliminary stages, this class of medication has the potential to prevent wet macular degeneration with one injection. These drugs accomplish long-lasting dosing by infecting retina cells with the gene for producing aflibercept (Eylea). Once infected, a retinal cell has the ability to produce a steady-state of anti-VEGF medication indefinitely. Early trials have indicated that 60% of patients injected with gene therapy were able to go at least one year without experiencing a recurrence of macular edema.
Call Us to Explore Options for Less-Frequent Eye Injections
Dr. Shane offers all of the latest FDA-approved options for less-frequent eye injections, including Susvimo. If you have wet macular degeneration and would like to explore how to get fewer injections while maintaining your vision, call or email us for a consultation. We are here to help you!